Celltrion Autoimmune Disease Treatment Receives Continued Orders in Europe

Celltrion is continuously supplying biosimilar products for autoimmune disease treatment to major European countries.

On the 12th, Celltrion announced that its autoimmune disease treatment 'Yuflyma' successfully won a provincial government tender in Italy. Yuflyma was awarded in the provincial government tenders held in Friuli Venezia Giulia (FVG) and Sicily, Italy.

With this contract, Yuflyma is scheduled to be supplied to FVG province for 4 years and 6 months, and to Sicily province for 2 years. Including this achievement, Celltrion secured contracts in a total of 12 provincial government tenders within Italy last year alone.

Yuflyma also won a tender in the Netherlands, where the European Medicines Agency (EMA) is located. It succeeded in the adalimumab tender held by ICZON, a pharmaceutical purchasing consortium in the southeastern region of the Netherlands. The supply is planned for the next 3 years.

Another autoimmune disease treatment, 'Remsima,' also succeeded in the infliximab tender held in Sicily, Italy, and is expected to be supplied for 2 years.

Celltrion further demonstrated product competitiveness by winning the Remsima tender at IZAAZ, a major pharmaceutical purchasing consortium in the Netherlands. IZAAZ is the largest university hospital group in the Netherlands. As of the third quarter of this year, Remsima holds a 54% market share in the Netherlands and ranks first in infliximab prescriptions. With this tender result, it is expected to maintain a more stable prescription trend.

Won-sik Yoo, head of Celltrion Italy, stated, "Yuflyma, a high-concentration formulation, has the advantage of enabling personalized treatment reflecting patients' conditions through dosage diversification, and is recognized for its product competitiveness as the biosimilar most similar to the original, leading to continuous prescription expansion. With the launch of the integrated Celltrion, cost ratio improvements will be achieved, enabling the establishment of a more differentiated pricing strategy. Based on this, we will continue to achieve positive results in upcoming tenders this year and drive the expansion of Celltrion products' sales."

This content was produced with the assistance of AI translation services.